[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-342086-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-342086-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advancements-in-leukemia-management-bridging-diagnosis-prognosis-and-nanotechnology-review","Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)","","Leukemia begins in bone marrow blood stem cells, and advances in diagnosis and prognosis are central to reducing morbidity and mortality. New biomarkers, especially minimal residual disease markers, support personalized therapeutic choices and enable quantitative monitoring of response. Genetic clinical parameters such as chromosomal abnormalities guide both diagnosis and treatment selection while offering prognostic value. This review synthesizes studies on diagnostic and prognostic parameters and highlights dominant clinical and laboratory approaches, plus surface-protein targets for nanocarrier drug delivery.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advancements-in-leukemia-management-bridging-diagnosis-prognosis-and-nanotechnology-review/342086/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advancements-in-leukemia-management-bridging-diagnosis-prognosis-and-nanotechnology-review/342086.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do minimal residual disease biomarkers support leukemia management?","Question",{"text":63,"@type":64},"They enable personalized therapeutic strategies and allow quantitative assessment of patient responses to treatment regimens.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which types of clinical features are commonly used for leukemia prognosis in the reviewed studies?",{"text":68,"@type":64},"Clinical and laboratory prognostic and hematologic parameters are reported as the most extensively studied, with clinical hematology being the predominant diagnostic and prognostic method.",{"name":70,"@type":61,"acceptedAnswer":71},"Why are nanocarriers important for targeted drug delivery to leukemia cells?",{"text":72,"@type":64},"They improve the precision of treatment directed at surface proteins and receptors, and they can be functionalized with targeting drugs and antibodies; they address delivery obstacles such as cellular heterogeneity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},342086,1790198759,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","INTERNATIONAL JOURNAL OF ONCOLOGY 65: 112, 2024  \nAdvancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review)  \nJINGBO LI 1 , YINGXUE WANG 1 , CHUNLI DONG2 and LIFU LUO3  \n1  \nDepartment of Ultrasound Medicine, The Second Hospital of Jilin University, Changchun, Jilin 130000, P.R. China; 2  \nDepartment of Critical Care Medicine, Jilin People's Hospital, Changchun, Jilin 130021, P.R. China; 3  \nDepartment of Ophthalmology, The Second Hospital of Jilin University, Changchun, Jilin 130000, P.R. China  \nReceived April 19, 2024; Accepted September 19, 2024  \nDOI: 10.3892/ijo.2024.5700  \nAbstract. Leukemia is a cancer that starts in blood stem cells in the bone marrow. Today, the proper diagnosis and prog‑ nosis of leukemia are essential in mitigating the morbidity and mortality associated with this malignancy. The advent of novel biomarkers, particularly those related to minimal residual disease, has paved the way for personalized thera‑ peutic strategies and enables the quantitative assessment of patient responses to treatment regimens . Novel diagnostic and targeted drug delivery may be helpful for the improved management of leukemia . Genetic clinical parameters, such as chromosomal abnormalities, are crucial in diagnosing and guiding treatment decisions. These genetic markers also provide valuable prognostic information, helping to predict patient outcomes and tailor personalized treatment plans. In the present review, the studies on the diagnostic and prog‑ nostic parameters of leukemia were analyzed. The prognosis of leukemia was investigated in most of the studies, and the remaining were performed on diagnosis. The clinical and labo‑ ratory prognostic parameters were the most common, followed by diagnostic hematological parameters, diagnostic blood parameter studies, and diagnostic immunological parameters. Clinical and laboratory prognostic and hematologic param‑ eters were the most extensively studied. The methods used to diagnose and prognose the leukemia cases in these studies were predominantly clinical hematology. Numerous surface proteins and receptors, including CD45, CD27, CD29, CD38, CD27, CD123, CD56 and CD25, react similarly in various kinds of leukemia, which are ideal for targeted drug delivery. Drug delivery to leukemia cells encounters several significant obstacles, including heterogeneity, that hinder the effectiveness of treatment. Nanocarriers play a critical role in targeted drug delivery for leukemia by enhancing the precision of treatments  \nCorrespondence to: Professor Lifu Luo, Department of Ophthalmology, The Second Hospital of Jilin University, 1556 Ziqiang Road, Changchun, Jilin 130000, P.R. China  \nE‑mail: [luolf@jlu.edu.cn](luolf@jlu.edu.cn)  \nKey words: leukemia, parameters, diagnostics, prognostics, cancer  \ndirected at surface proteins and receptors. Additionally, they can be functionalized with targeting drugs and antibodies to target specific tissues and cells.  \nContents  \n1. Introduction  \n2. Methods  \n3. Key findings from leukemia diagnostic and prognostic studies  \n4. Critical assessment of diagnostic and prognostic develop‑ ments in leukemia  \n5. Exploring diagnostic parameters in leukemia  \n6. Identifying key prognostic parameters in leukemia  \n7. Conclusion  \n1. Introduction  \nLeukemia refers to a category of blood malignancies charac‑ terized by the excessive production of abnormal blood cells and an underlying propensity for the bone marrow to serve as cancer's site of origin (1). Malignant cells use up healthy bone marrow cells to grow, leaving the body without enough plate‑ lets and normal white blood cells (WBCs) to prevent bleeding and fight infection (2‑4) . It is a somatic mutation‑driven hematological clonal neoplasm (5‑7) . Neoplastic cells can self‑replicate, develop, and feed progenitor cells such as hema‑ topoietic cells, exhibiting similar behaviour (8‑10) . Leukemic unipotent stem cells can differentiate into phenotypes of adult blood ","cbCaijjm2Te3OCjc","https://ap.wps.com/l/cbCaijjm2Te3OCjc","pdf",3514768,23,"English","# Introduction\n# Methods\n## Key findings from leukemia diagnostic and prognostic studies\n## Critical assessment of diagnostic and prognostic developments in leukemia\n## Exploring diagnostic parameters in leukemia\n## Identifying key prognostic parameters in leukemia\n## Conclusion","[{\"question\":\"How do minimal residual disease biomarkers support leukemia management?\",\"answer\":\"They enable personalized therapeutic strategies and allow quantitative assessment of patient responses to treatment regimens.\"},{\"question\":\"Which types of clinical features are commonly used for leukemia prognosis in the reviewed studies?\",\"answer\":\"Clinical and laboratory prognostic and hematologic parameters are reported as the most extensively studied, with clinical hematology being the predominant diagnostic and prognostic method.\"},{\"question\":\"Why are nanocarriers important for targeted drug delivery to leukemia cells?\",\"answer\":\"They improve the precision of treatment directed at surface proteins and receptors, and they can be functionalized with targeting drugs and antibodies; they address delivery obstacles such as cellular heterogeneity.\"}]","Advancements in leukemia management: Bridging diagnosis, prognosis and nanotechnology (Review) | PDF",1790045110,58,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28dac8415ba2fcdbea9c66ee30082ccc.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc9e6057d48c4f35a88676a0985b5fce.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e065f5afaeb34b5f42f9da53e25b3744.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/411ed384edbe2dc2bc213f3b373cfe79.webp",980,1353]